Experts debate cutting-edge multiple myeloma treatments, exploring pressing data, the most prominent news, and patient cases.

Results from a retrospective study showed that chemoimmunotherapy did not prolong survival vs chemotherapy in a younger ES-SCLC population.

Geraldine O’Sullivan Coyne, MD, MRCPI, PhD, described the excitement of seeing novel molecules like antibody drug conjugates become more prominent.

Panelists discuss how their key takeaways emphasize the importance of communication and collaboration between academic centers and community practices...

Panelists discuss how to implement hepatotoxicity monitoring protocols, counsel patients about avoiding hepatotoxic substances, and manage the infrequ...

The primary end points of the EPCORE FL-1 trial were met while assessing an epcoritamab-based combination for patients with R/R follicular lymphoma.

Panelists discuss how voracidinib shows superior brain penetration compared to other IDH inhibitors and explore exciting combination approaches with i...

Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovat...

An update of phase 1 data from the CTMX-2051-101 study is expected to be available by the first quarter of 2026.

Results from the phase 3 KEYNOTE-689 trial supported the agency’s approval of the pembrolizumab/surgery regimen in PD-L1–positive head and neck cancer...